Paper26733552
Prostate Cancer, Version 1.2016.
Mohler JL and 31 others. J Natl Compr Canc Netw, 2016. Cited by 528 papers, by iCite.
Cite this record
ConductScience Library. Prostate Cancer, Version 1.2016. Papers, record 26733552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26733552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Disease Progression | |
| Humans | |
| Male | |
| Neoplasm Staging | |
| Orchiectomy | |
| Prognosis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA060553 | NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 27639611 | Editorial Comment. | https://conductscience.org/library/papers/27639611 |
Source PubMed
Cited by293
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 528 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42840510 | SWI/SNF chromatin remodelers in prostate cancer progression. | Front Epigenet Epigenom | 2023 | https://conductscience.org/library/papers/42840510 | PubMed |
| 42666623 | Salvage prostate therapies for local pelvic recurrence after primary radiation for prostate cancer. | BJUI Compass | 2026 | https://conductscience.org/library/papers/42666623 | PubMed |
| 42528154 | Trends in the Adoption of MRI Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A SEER-Medicare Cohort Study. | Cancer Med | 2026 | https://conductscience.org/library/papers/42528154 | PubMed |
| 42211501 | Update of the MSKCC nomogram for metastatic progression and its role in active surveillance: the Italian TPCP cohort. | Front Oncol | 2026 | https://conductscience.org/library/papers/42211501 | PubMed |
| 41827775 | mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active Surveillance. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41827775 | PubMed |
| 40759791 | New frontiers in prostate cancer treatment from systemic therapy to targeted therapy. | EMBO Mol Med | 2025 | https://conductscience.org/library/papers/40759791 | PubMed |
| 40698265 | Adaption of the Memorial Sloan Kettering Cancer Center Nomograms for the Prediction of Prostate Cancer-specific Death in Sweden: A Population-based Cohort Study. | Eur Urol Open Sci | 2025 | https://conductscience.org/library/papers/40698265 | PubMed |
| 40614127 | Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance. | Cancer | 2025 | https://conductscience.org/library/papers/40614127 | PubMed |
| 40586954 | Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimen. | World J Urol | 2025 | https://conductscience.org/library/papers/40586954 | PubMed |
| 40426959 | Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review. | Biomedicines | 2025 | https://conductscience.org/library/papers/40426959 | PubMed |
| 40276087 | Real‑world data on the outcomes of upfront docetaxel in hormone‑sensitive metastatic prostate cancer. | Oncol Lett | 2025 | https://conductscience.org/library/papers/40276087 | PubMed |
| 39859516 | Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39859516 | PubMed |
| 39816941 | Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study. | Prostate Int | 2024 | https://conductscience.org/library/papers/39816941 | PubMed |
| 39539558 | Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance. | BJUI Compass | 2024 | https://conductscience.org/library/papers/39539558 | PubMed |
| 39528898 | Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohort. | Int Urol Nephrol | 2025 | https://conductscience.org/library/papers/39528898 | PubMed |
| 39410925 | Prognostic value of three clinical nutrition scoring system (NRI, PNI, and CONUT) in elderly patients with prostate cancer. | Front Nutr | 2024 | https://conductscience.org/library/papers/39410925 | PubMed |
| 39410867 | Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/39410867 | PubMed |
| 39272888 | Traditional Prostate Cancer Risk Assessment Scales Do Not Predict Outcomes from Brain Metastases: A Population-Based Predictive Nomogram. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39272888 | PubMed |
| 39176293 | The association of type and number of high-risk criteria with cancer-specific mortality in prostate cancer patients treated with radical prostatectomy. | Curr Urol | 2024 | https://conductscience.org/library/papers/39176293 | PubMed |
| 39143030 | Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. | Cancer Med | 2024 | https://conductscience.org/library/papers/39143030 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26733552
GET https://conductscience.org/api/papers/v1/26733552/authors?page=2